The Cooperative Signaling of Src and MAPK Pathways in Thyroid Cancer
MMK Rose - 2023 - search.proquest.com
Patients with advanced thyroid cancer, which include radioactive iodine-resistant (RAI-R)
differentiated thyroid cancer, poorly differentiated (PDTC), and anaplastic thyroid cancer …
differentiated thyroid cancer, poorly differentiated (PDTC), and anaplastic thyroid cancer …
[PDF][PDF] Importance of the RET mutation in lung cancer
ABMA Rocha - 2023 - repositorio-aberto.up.pt
Background: Lung cancer is the leading cause of death by cancer worldwide, and also one
of the most diagnosed cancers, only behind the two main sex-specific cancers: breast and …
of the most diagnosed cancers, only behind the two main sex-specific cancers: breast and …
Impact of tyrosine kinase inhibitors and bone morphogenetic proteins on persistent leukemic stem cell dormancy in Chronic Myeloid Leukemia patients at remission
K Arizkane - 2022 - theses.hal.science
Despite the therapeutic progress of Chronic Myeloid Leukemia (CML) due to the Tyrosine
Kinase Inhibitors (TKIs) that targets specifically BCR-ABL kinase, TKI treatment is not yet …
Kinase Inhibitors (TKIs) that targets specifically BCR-ABL kinase, TKI treatment is not yet …
Substanzen gegen molekulare Zielstrukturen
K Zirlik, J Duyster - … Internistische Onkologie: Standards in Diagnostik und …, 2022 - Springer
Das stetig wachsende Verständnis der molekularen Pathogenese maligner Tumoren und
insbesondere die detaillierte Charakterisierung krebstreibender Mutationen, die sowohl die …
insbesondere die detaillierte Charakterisierung krebstreibender Mutationen, die sowohl die …
[PDF][PDF] p90RSK Regulates p53 Pathway by MDM2 Phosphorylation in Thyroid Tumors
V De Falco - 2023 - videleaf.com
The expression level of the tumor suppressor p53 is controlled by the E3 ubiquitin ligase
MDM2 with a regulatory feedback loop, which allows p53 to up regulate its inhibitor MDM2 …
MDM2 with a regulatory feedback loop, which allows p53 to up regulate its inhibitor MDM2 …
RET 基因在肺癌中的研究进展
马晨璐， 俞婷婷， 单莉 - 医学综述, 2017 - cqvip.com
RET 原癌基因已经逐渐被证实与多种恶性肿瘤的发生, 发展具有相关性, 伴着分子靶向研究的
热潮. RET 基因的融合突变在肺癌患者中被发现, 提示肺癌精准治疗的新靶点出现. RET …
热潮. RET 基因的融合突变在肺癌患者中被发现, 提示肺癌精准治疗的新靶点出现. RET …
Медулярний рак щитоподібної залози
ВГ Мішалов, АВ Дінець - Хірургія дитячого віку, 2014 - irbis-nbuv.gov.ua
Здійснений аналіз літературних джерел свідчить про важливість використання
секвенсингу протоонкогена RET з метою ранньої діагностики медулярного раку …
секвенсингу протоонкогена RET з метою ранньої діагностики медулярного раку …
Alkynyl nicotinamide compounds as kinase inhibitors
HO Sintim, E Larocque, N Naganna - US Patent App. 17/274,950, 2022 - Google Patents
US20220089599A1 - Alkynyl nicotinamide compounds as kinase inhibitors - Google
Patents US20220089599A1 - Alkynyl nicotinamide compounds as kinase inhibitors …
Patents US20220089599A1 - Alkynyl nicotinamide compounds as kinase inhibitors …
Development of novel receptor tyrosine kinase inhibitors by a chemocentric approach
SH Myers - 2017 - era.ed.ac.uk
In recent years, there has been a major movement in the pharmaceutical industry towards
the development of molecules that selectivity inhibit a previously-validated specific target …
the development of molecules that selectivity inhibit a previously-validated specific target …
Ponatinib shows potent antitumor activity in small cell carcinoma of the ovary hypercalcemic type (SCCOHT) through multi-kinase inhibition
Structured Abstract Purpose: Subunits of the SWI/SNF chromatin-remodeling complex are
tumor suppressors inactivated in∼ 20% of all cancers. Yet, few targeted treatments for …
tumor suppressors inactivated in∼ 20% of all cancers. Yet, few targeted treatments for …